Doctors at Brigham and Women’s Test Mesothelioma Therapies on Mice
Treatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
Testimonials
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
APA
Povtak, T. (2020, October 16). Doctors at Brigham and Women’s Test Mesothelioma Therapies on Mice. Asbestos.com. Retrieved February 4, 2023, from https://www.asbestos.com/news/2011/10/11/mice-lending-help-at-brigham-and-womens-with-mesothelioma-fight/
MLA
Povtak, Tim. "Doctors at Brigham and Women’s Test Mesothelioma Therapies on Mice." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2011/10/11/mice-lending-help-at-brigham-and-womens-with-mesothelioma-fight/.
Chicago
Povtak, Tim. "Doctors at Brigham and Women’s Test Mesothelioma Therapies on Mice." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2011/10/11/mice-lending-help-at-brigham-and-womens-with-mesothelioma-fight/.
At the acclaimed Brigham and Women’s Hospital and Harvard Medical School in Boston, it’s usually the thoracic surgeons, oncologists or pathologists getting the credit for advancing the fight against malignant mesothelioma.
This time, it’s the mice.
With a rare cancer like mesothelioma, research scientists often don’t have enough real test cases to use in their search for better adjuvant therapies, needing subjects who first have had surgery.
That’s where the lab mice are contributing now.
Scientists at Brigham & Women’s Hospital have been grafting human mesothelioma cells into the mice, letting them grow, then surgically removing the tumors from the peritoneal cavities, giving them viable test subjects for adjuvant therapies.
Before closing the surgical openings, researchers were applying intracavitary chemotherapy, allowing them to evaluate the chemotherapy drug, paclitaxel, using expansile nanoparticles.
And what they found was encouraging, something they could not have discovered without the help of the mice.
Although paclitaxel has been tested alone as a chemotherapy drug, in both mice and humans, researchers wanted to gauge its effectiveness as part of the multi-modal approach that has become so popular.
Malignant mesothelioma cancer stems from an exposure to asbestos and has a particularly poor prognosis, making even the smallest advancements important.
“Treatment with Pax-eNP (paclitaxel) improved overall survival in the setting of CRS (cytoreductive surgery), suggesting that [it] merits further evaluation for intracavitary drug delivery following the surgical resection of malignant mesothelioma,” concluded the testing.
The paclitaxel-loaded nanoparticles were designed to kill off any mesothelioma cells that remained after the surgery. The mice were assessed for 90 days after surgery. The ones which had paclitaxel in addition to the surgery survived longer than the ones which had surgery alone. The conclusion was that surgery alone did not prolong survival, and confirmed the belief that combination therapy worked best.
The cytoreductive surgery in mice incurred less than a 5 percent operative mortality, making it feasible and reproducible.
